Tumor marker expression is predictive of survival in patients with esophageal cancer

被引:50
作者
Aloia, TA
Harpole, DH
Reed, CE
Allegra, C
Moore, MBH
Herndon, JE
D'Amico, TA
机构
[1] Duke Univ, Med Ctr, Div Cardiothorac Surg, Durham, NC 27710 USA
[2] Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA
[3] NCI, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S0003-4975(01)02838-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. This study was designed to determine the prognostic value of immunohistochemical tumor marker expression in a population of patients with node-negative esophageal cancer treated with complete resection alone. Methods. Resection specimens were collected from 61 patients with node-negative T1 (n = 31), T2 (n = 14), and T3 (n = 16) esophageal cancer. A panel of 10 tumor markers was chosen for immunohistochemical analysis, based on associations with differing oncologic mechanisms: apoptosis (p53), growth regulation (transforming growth factor-alpha, epidermal growth factor receptor, and Her2-neu), angiogenesis (factor VIII), metastatic potential (CD44), platinum resistance (p-glycoprotein and metallothionein), 5-fluorouracil resistance (thymidylate synthetase), and carcinogenic detoxification (glutathione S-transferase-pi). Results. Complete resection was performed in all patients (44 adenocarcinoma, 17 squamous cell carcinoma), with no operative deaths. Multivariable analysis demonstrated a significant relationship between cancer-specific death and the following variables: low-level P-gp expression (p = 0.004), high-level expression of p53 (p = 0.04), and low-level expression of transforming growth factor-alpha (P = 0.03). In addition, the number of involved tumor markers present was strongly predictive of negative outcome (p = 0.0001). Conclusions. This study supports the prognostic value of immunohistochemical tumor markers, specifically the expression pattern of P-gp, p53, and transforming growth factor-alpha, in patients with esophageal carcinoma treated with complete resection alone. (C) 2001 by The Society of Thoracic Surgeons.
引用
收藏
页码:859 / 866
页数:8
相关论文
共 22 条
[1]   AMPLIFICATION AND OVER-EXPRESSION OF THE EGFR AND ERBB-2 GENES IN HUMAN ESOPHAGEAL ADENOCARCINOMAS [J].
ALKASSPOOLES, M ;
MOORE, JH ;
ORRINGER, MB ;
BEER, DG .
INTERNATIONAL JOURNAL OF CANCER, 1993, 54 (02) :213-219
[2]   Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus [J].
Bosset, JF ;
Gignoux, M ;
Triboulet, JP ;
Tiret, E ;
Mantion, G ;
Elias, D ;
Lozach, P ;
Ollier, JC ;
Pavy, JJ ;
Mercier, M ;
Sahmoud, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :161-167
[3]  
Böttger TG, 1998, CANCER-AM CANCER SOC, V83, P1074, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1074::AID-CNCR4>3.0.CO
[4]  
2-8
[5]   p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival [J].
Casson, AG ;
Tammemagi, M ;
Eskandarian, S ;
Redston, M ;
McLaughlin, J ;
Ozcelik, H .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1998, 51 (02) :71-79
[6]  
D'Amico T A, 2000, Chest Surg Clin N Am, V10, P451
[7]   A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers [J].
D'Amico, TA ;
Massey, M ;
Herndon, JE ;
Moore, MB ;
Harpole, DH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (04) :736-742
[8]   Immunohistochemical determination of thymidylate synthase in colorectal cancer - methodological studies [J].
Edler, D ;
Blomgren, H ;
Allegra, CJ ;
Johnston, PG ;
Lagerstedt, U ;
Magnusson, I ;
Ragnhammar, P .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (13) :2278-2281
[9]  
FLEMING ID, 1997, AJCC CANC STAGING MA, P65
[10]  
Gerdes AM, 1998, ANTICANCER RES, V18, P2529